Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues

Home > Science Hub > Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues
Back to the list

November 9, 2020

Maxim Isabelle, Michael Schirm, Gwenaël Pottiez, Rudolf Guilbaud and Lorella Di Donato

Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues, SITC 2020

Capion_Poster_SITC_FFPE

 

Download the poster

You might also be interested by

Infographics

Supporting Your Targeted Protein Degradation Strategies

January 31, 2023

Proteomics/Mass Spectrometry

More info

CellTalk

Landmark study on metastatic breast cancer highlights the importance of identifying HER2-low patients

June 23, 2022

Proteomics/Mass Spectrometry

More info

Press Releases

CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays

May 19, 2022

Proteomics/Mass Spectrometry

More info

Brochures

High Performance Technologies for Cytokine Measurement

November 8, 2021

Immune Monitoring

More info